key: cord-0885628-7gdwl5gt
authors: Koletsi, Patra; Antoniadi, Marita; Mermiri, Despina; Koltsida, Georgia; Koukou, Dimitra; Noni, Maria; Spoulou, Vasiliki; Michos, Athanasios
title: A toddler diagnosed with severe postinfectious bronchiolitis obliterans and COVID‐19 infection
date: 2021-05-04
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.25436
sha: c063b2e2ccb6c080cc87cf4ce97cd3809b290dab
doc_id: 885628
cord_uid: 7gdwl5gt

During the COVID‐19 pandemic, management of SARS‐CoV‐2 infection in children with underlying chronic lung disease has been challenging. There are limited studies in children with respiratory comorbidities, apart from asthma, presumably due to low morbidity of SARS‐CoV‐2 infection in the general pediatric population along with the low incidence of certain pulmonary conditions. Compassionate use of remdesivir has been shown to reduce time to clinical improvement in adults and has been retrospectively studied in small pediatric cohorts with promising results. Whether children with underlying respiratory conditions may benefit from antiviral treatment in the context of different pathophysiologic backgrounds and unknown drug safety and efficacy needs to be further evaluated. We present a case of COVID‐19 infection in a 3‐year old toddler with severe postinfectious bronchiolitis obliterans, who received compassionate treatment with 5‐day‐course of remdesivir, and recovered with favourable outcome.

with the low incidence of certain pulmonary conditions. Compassionate use of remdesivir has been shown to reduce time to clinical improvement in adults and has been retrospectively studied in small pediatric cohorts with promising results. There are limited studies in children with respiratory comorbidities, apart from asthma, presumably due to low morbidity of SARS-CoV-2 infection in the general paediatric population along with the low incidence of certain pulmonary conditions. [1] [2] [3] Remdesivir, a broad spectrum antiviral agent against several RNA viruses, has been shown to reduce time to clinical improvement in adults and has been retrospectively studied in small pediatric cohorts with promising results. In anticipation of randomized controlled trials for the pediatric population, an expert consensus suggests the use of antivirals in children on a case-by-case basis. 2, 3 We present a case of COVID-19 infection in a 3-year old toddler with severe postinfectious bronchiolitis obliterans (PIBO), who received compassionate treatment with 5-day-course of remdesivir, and recovered with favourable outcome.

The patient is a 3-year-old toddler, without significant perinatal complications, who was diagnosed with PIBO at the age of 13 months, following an RSV and adenovirus coinfection. He was hospitalized for approximately 12 months due to difficulty in weaning off invasive and noninvasive respiratory support. He received multiple courses of pulse methylprednisolone treatment (10-30 mg/kg) and was placed on long term treatment with inhaled fluticasone and salbutamol, low dose oral azithromycin and oral montelukast (FAM).

His HRCT chest demonstrates bronchial thickening, ground glass opacities, severe air trapping bilaterally and bronchiectasis ( Figure 1A ,B).

Since his discharge, at the age of 22 months, he remains on the FAM treatment and receives supplemental oxygen during the day (1-2 L/min) and nocturnal noninvasive ventilation (BLPAP). He is steroid-responsive and requires a pulse dose of methylprednisolone (10 mg/kg) every 4-6 weeks in line with his respiratory status.

To date, he has established mixed hypercapnic and hypoxemic respiratory failure and a profound exercise intolerance. At baseline, he has tachypnea, subcostal and suprasternal retractions, diminished respiratory sounds, fine crackles on lung auscultation and hyperresonance on percussion.

This patient presented at the Emergency Room due to fever 24 h before his admission, tired-appearing, with worsening tachypnea and mildly increased oxygen needs to 3 L/min. COVID-19 infection was confirmed by molecular testing in nasopharyngeal swab (cycle threshold 21) and chest X-ray showed peribronchial thickening and severe hyperinflation ( Figure 1C ). Laboratory evaluation revealed normal inflammatory biomarkers ( Table 1 ). The patient was transferred to the COVID-19 Department for further management.

Upon arrival, the patient was initiated on broad spectrum antibiotics and intravenous dexamethasone at a dose of 0.15 mg/kg for 5 days and weaning thereafter, for another 5 days. Following parental informed consent, a compassionate access application for Emergency Use Authorisation of remdesivir was requested and granted by the National Organisation for Health Care Provision. On day 4 from disease onset, an intravenous loading dose of remdesivir (5 mg/kg) was administered, followed by 2.5 mg/kg maintenance dose for 5 days with continuous hepatic and renal function monitoring.

No associated drug toxicity was observed. Fever regressed and the patient returned to baseline oxygen requirements (2 L/min) within 24 h from remdesivir administration. He was discharged after 11 days of hospitalization, on baseline respiratory support. Follow-up examinations did not show signs of COVID-19 sequelae, his chest radiograph three months post COVID-19 course did not show significant changes and his baseline oxygen support remains unaltered ( Figure 1D ). Similarly, there is no pediatric-specific evidence that remdesivir mitigates disease severity.

As the great majority of children suffer minimal symptoms, anyone could question if the potential benefits of antivirals are also limited and, therefore, the threshold of using it should be much higher, given the unknown side effects. In our case, remdesivir was well tolerated, although, it is impossible to determine its contribution to our patient's uneventful recovery.

In conclusion, this unprecedented pandemic has put many clinicians under intense pressure to provide equivocal therapies based on compelling preclinical data. We feel that remdesivir may have contributed to our patient's relatively quick recovery, 

COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres

ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Compassionate use of remdesivir in children with COVID-19

Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2

Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy